Paul Hennessey, Senior Vice President - Sales & Business Development
While the quest for innovative drugs picks up steam among leading pharmaceutical organizations, contract development and manufacturing organizations (CDMOs) continue to be weighed down by diminishing operating efficiency and spiking drug manufacturing costs. Addressing these setbacks, Hauppauge-based Contract Pharmacal Corp. (CPC) has set a new paradigm in the CDMO industry as the most trusted market-leading provider of high-quality, affordable pharmaceutical and nutritional products. Since opening its doors in 1971, CPC—a second generation, family owned company operated by brothers Matthew and Mark Wolf—has been defining the standards of excellence that are critical to the health and well-being of communities. “Our owners have a consistent track record of reinvesting into the business with advanced technology and new equipment to keep us up-to-date and on the cutting edge of everything we need to be a leading CDMO,” begins Paul Hennessey, Senior Vice President of Sales and Business Development at Contract Pharmacal Corp.
With its manufacturing operations entirely based in the U.S., CPC’s core competency lies in developing, manufacturing, and packaging solid dose drugs—over the counter and prescription— that include tablets, capsules, powders, and dietary supplements to cater to their growing need in the global market. Hennessey adds, “While numerous companies in our industry choose to outsource their manufacturing, we excel at bringing unprecedented efficiency to the table by focusing solely on solid dose manufacturing.” In addition, CPC enables customers to enjoy the benefits of scale; “we now have two 400 cubic foot blenders that allow us to manufacture massive batches of up to 8,000 kilos.” As such, the company invariably helps customers reduce their manufacturing costs by increasing their batch sizes, allowing them to be more competitive in the market.
CPC has constantly delivered the highest quality of dosage form, all the way from chewable, orally-dissolving, swallowable, and bi-layer tablets to hard-shell capsules containing powders, pellets, or both. In terms of packaging, CPC provides an array of solutions comprising sachets, stick packs, bottles, pouches, vials, blisters, cartons, and more through its high-speed, fully automated packaging lines with in-line cartoning. “We are one of the few companies that are producing dietary supplements within the factories governed by cGMPs used for drug products,” Hennessey remarks. In one instance, a large pharmaceutical company approached CPC for a stick pack project with multiple doses including one at an extremely low fill weight. Drawing on their deep expertise in stick pack projects, CPC’s engineering, validation, and R&D teams collaborated with the client, and successfully assisted them with their exhibit batches within a tight schedule.
While numerous companies in our industry choose to outsource their manufacturing, we excel at bringing unprecedented efficiency to the table by focusing solely on solid dose manufacturing
Hennessey underscores that CPC helps clients save considerable time by performing their product testing within their internal laboratories. Added to that, CPC’s astute project management group with highly skilled professional project managers assists clients with unparalleled project management capabilities. From quoting an item, preparing a proposal, all the way through validation and commercial launch, CPC’s dedicated project managers track and monitor every single aspect to deliver a program on time and within budget. As a science-based development organization, the company also conducts cross-training between its R&D teams in India and the US, leveraging deep, analytical and formulation R&D to successfully drive projects.
Fostering a culture of collaboration, honesty, and accountability, CPC is committed to quality, efficiency, and service and considers clients' needs as the utmost priority. Currently, the company is going through a major expansion that will add additional capacity and new equipment in blending, granulation, tablet compression, encapsulation, and coding. Hennessey concludes, “We recently announced a $40 Mn investment in a new manufacturing facility to increase our capacity and be able to make 40 Mn doses a year.”